|
Enalapril After Anthracycline Cardiotoxicity Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Enalapril After Anthracycline Cardiotoxicity conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Enalapril After Anthracycline Cardiotoxicity Clinical research trials and Enalapril After Anthracycline Cardiotoxicity healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Enalapril After Anthracycline Cardiotoxicity. Enalapril After Anthracycline Cardiotoxicity Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Enalapril After Anthracycline Cardiotoxicity clinical trial. Human subjects often obtain the finest healthcare possible for their Enalapril After Anthracycline Cardiotoxicity condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Enalapril After Anthracycline Cardiotoxicity  Enalapril After Anthracycline Cardiotoxicity
Enalapril After Anthracycline Cardiotoxicity
For Condition: Cardiovascular Diseases,Heart Diseases,Heart Failure,Myocardial Diseases
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To determine if the chronic administration of enalapril, an inhibitor of angiotensin converting enzyme (ACE), reduces progression of cardiac dysfunction in pediatric oncology patients who have received anthracyclines, and who are not currently on digoxin, diuretics, or vasodilators for heart failure.
Details: BACKGROUND: Pediatric oncology patients who have been treated with anthracycline therapy as a part of their chemotherapeutic regimen often subsequently develop left ventricular failure. The optimal medical management is not known. This trial will be the first to provide comprehensive data on a well characterized population regarding the role of afterload reduction using enalapril to treat ventricular dysfunction after anthracycline chemotherapy DESIGN NARRATIVE: Randomized, double-blind. Randomization was stratified by total anthracycline dose, follow-up time from treatment, and age at time of treatment. All patients received the following baseline tests: Maximal Cardiac Index (MCI) on cycle ergometry; echocardiogram/Doppler determined left ventricular end systolic wall stress (ESWS); gated nuclear angiography (GNA) to determine left ventricular ejection fraction; Holter monitoring for 24 hour ECG monitoring. Patients were randomized to either enalapril or placebo. Follow-up visits were conducted to ensure compliance and screen for side effects. MCI and ESWS were measured twice yearly, while all four tests were repeated at the conclusion of the trial, after four to five years of treatment. The primary outcome variables were the rate of decline in MCI and the rate of increase in ESWS. Secondary outcomes were the change in left ventricular ejection fraction and the incidence of arrhythmias. A second aim of the study was to develop an algorithm to determine indications for enalapril use if the study succeeded in showing a treatment effect. This required modeling the probability of cardiac dysfunction given patient characteristics at treatment, treatment type, cardiac status during treatment and at follow-up, and the development of cost effectiveness and medical decision making models testing the proposed algorithm.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control
Minimum Age/Maximum Age: 1 Year/17 Years
Genders: Both
Protocol Entry Criteria: Boy and girl pediatric oncology patients, at least two years off treatment, with some cardiac dysfunction, but not congestive heart failure, after receiving anthracyclines. Patients were not on digoxin, diuretics, or vasodilators for heart failure.
Total Enrollment:
Location and Contact Information:
Overall Study Official:
JeffreySilber, , Children's Hospital of Philadelphia
Additional Information:
Study ID Numbers: 91;
Study Start Date: April 1994
Record last reviewed: January 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000547
Other Cardiovascular Diseases Studies:
1. AIDS-Associated Heart Disease -- Incidence and Etiology
2. Pediatric Cardiomyopathy Registry
3. Enalapril After Anthracycline Cardiotoxicity
4. Chagas Disease as an Undiagnosed Type of Cardiomyopathy in the United States
5. Epidemiology of Idiopathic Dilated Cardiomyopathy (Washington, DC Dilated Cardiomyopathy Study)
Related Studies:
Other Cardiovascular Diseases Clinical Trials
Other Clinical Trials
Other Clinical Trials
Enalapril After Anthracycline Cardiotoxicity
|
|
|
|
|
|
|
|
